Registry of Patients With Generalized Myasthenia Gravis Who Have Ever Been Treated With C5 Inhibition Therapies
- Study HIC#:2000026785REG
- Last Updated:11/20/2023
If you have generalized myasthenia gravis (gMG) and have been treated with complement component 5 inhibition therapies (C5IT) you may be eligible to participate in a registry to see how well C5IT treats gMG over time, and to help us learn more about the safety of this therapy.
Contact Us
For more information about this study, including how to volunteer, contact:
Danielle Carlson
- Phone Number: 1-203-785-2253
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Trial Purpose and Description
The purpose of the Registry is to collect data to address several research objectives. This is a long-term, multicenter, observational, registry of patients with gMG who are treated with C5IT prior to enrollment.
Eligibility Criteria
To pre-qualify for this study, you must:
• Be 18 years of age or older
• Have been diagnosed with gMG
• Have ever been treated with ALXN-C5IT (Soliris or Ultomiris)
- Additional criteria will apply.
Principal Investigator
- Score: 1
